COVID-19 infection in gastrointestinal (GI) cancer patients receiving systemic anticancer treatment (SACT) during the outbreak of the pandemic: The Guy's Cancer Centre experience.
Eirini Tsotra(Guy's and St Thomas' NHS Foundation Trust), Saoirse Dolly(Guy's and St Thomas' NHS Foundation Trust), Charalampos Gousis(Guy's and St Thomas' NHS Foundation Trust), Kieran Palmer(Guy's and St Thomas' NHS Foundation Trust), N. Maisey(Guy's Hospital), Anne Rigg(National Health Service), Kasia Owczarczyk(King's College London), Jose Roca(Guy's and St Thomas' NHS Foundation Trust), Ailsa Sita-Lumsden(Guy's and St Thomas' NHS Foundation Trust), Julien de Naurois(Guy's and St Thomas' NHS Foundation Trust), Charlotte Moss(Southampton General Hospital), Kiruthikah Thillai(Guy's and St Thomas' NHS Foundation Trust), Paul J. Ross(King's College Hospital NHS Foundation Trust), Beth Russell(King's College London), Debashis Sarker(King's College - North Carolina), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Asad Qureshi(Guy's and St Thomas' NHS Foundation Trust), Victoria Harris(University of Oxford), Sarah Ngan(Guy's and St Thomas' NHS Foundation Trust), Mieke Van Hemelrijck(Ghent University Hospital)
Cited by 1
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Prevalence and demography of transsexualism in Belgium
|European Psychiatry|2007|306